Jentashapir Journal of Health Research

Published by: Kowsar

Comparison of the Effects of CinnoVex, Rebif and Betaferon on a Expanded Disability Status Scale of Patients With Multiple Sclerosis

Nastaran Madjdinasab 1 , * , Seyed Ehsan Mohammadiany Nejad 1 , Shahram Tarahomi 1 , Fatemeh Sadr 1 and Mohammad Bahadoram 1
Authors Information
1 Department of Neurology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
Article information
  • Jentashapir Journal of Health Research: June 01, 2015, 6 (3); e29201
  • Published Online: June 27, 2015
  • Article Type: Research Article
  • Received: November 12, 2014
  • Accepted: December 28, 2014
  • DOI: 10.5812/jjhr.6(3)2015.29201

To Cite: Madjdinasab N, Mohammadiany Nejad S E, Tarahomi S, Sadr F, Bahadoram M. et al. Comparison of the Effects of CinnoVex, Rebif and Betaferon on a Expanded Disability Status Scale of Patients With Multiple Sclerosis, Jentashapir J Health Res. 2015 ;6(3):e29201. doi: 10.5812/jjhr.6(3)2015.29201.

Abstract
Copyright © 2015, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
References
  • 1. Mazdeh M, Afzali S, Jaafari MR. The therapeutic effect of Avonex, Rebif and Betaferon on EDSS and relapse in multiple sclerosis: a comparative study. Acta Med Iran. 2010; 48(2): 83-8[PubMed]
  • 2. Etemadifar M, Mazdeh M, Torabi HR, Ghaffarpour M, Azimian M, Salami S, et al. A report of multiple sclerosis patients treated by CinnoVex in Iran. Tehran Univ Med Sci. 2010; 68(1): 30-6
  • 3. Weinstock-Guttman B, Bakshi R. Combination therapy for multiple sclerosis: the treatment strategy of the future? CNS Drugs. 2004; 18(12): 777-92[DOI][PubMed]
  • 4. Ebers GC. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet. 1998; 352(9139): 1498-504[DOI]
  • 5. Pozzilli C, Prosperini L, Sbardella E, De Giglio L, Onesti E, Tomassini V. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience. Neurol Sci. 2005; 26(4)-8
  • 6. Olek MJ, Dawson DM. Multiple sclerosis and other inflammatory demyelinating diseases of the central nervous system. 2004; : 1631-64
  • 7. Cottrell DA, Kremenchutzky M, Rice GPA, Koopman WJ, Hader W, Baskerville J, et al. The natural history of multiple sclerosis: A geographically based study. Brain. 1999; 122(4): 625-39
  • 8. Kremenchutzky M, Cottrell D, Rice G, Hader W, Baskerville J, Koopman W, et al. The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain. 1999; 122 ( Pt 10): 1941-50[PubMed]
  • 9. IFNB Multiple Sclerosis Study Group . Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis I. Clinical results of a multicenter, randomized, double‐blind, placebo-controlled trial. Neurol. 1993; 43(4): 655
  • 10. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996; 39(3): 285-94[DOI][PubMed]
  • 11. Claire SR, Mark JT. Merritt's Neurology. 2005; : 958-60
  • 12. Etemadifar M, Janghorbani M, Shaygannejad V. Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. Acta Neurol Scand. 2006; 113(5): 283-7[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments